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BACKGROUND: Social recognition underlies social behavior in animals, and patients with psychiatric disorders
associated with social deﬁcits show abnormalities in social recognition. Oxytocin is implicated in social behavior and
has received attention as an effective treatment for sociobehavioral deﬁcits. Secretin receptor–deﬁcient mice show
deﬁcits in social behavior. The relationship between oxytocin and secretin concerning social behavior remains to be
determined.
METHODS: Expression of c-Fos in oxytocin neurons and release of oxytocin from their dendrites after secretin
application were investigated. Social recognition was examined after intracerebroventricular or local injection of
secretin, oxytocin, or an oxytocin receptor antagonist in rats, oxytocin receptor–deﬁcient mice, and secretin
receptor–deﬁcient mice. Electron and light microscopic immunohistochemical analysis was also performed to
determine whether oxytocin neurons extend their dendrites into the medial amygdala.
RESULTS: Supraoptic oxytocin neurons expressed the secretin receptor. Secretin activated supraoptic oxytocin
neurons and facilitated oxytocin release from dendrites. Secretin increased acquisition of social recognition in an
oxytocin receptor–dependent manner. Local application of secretin into the supraoptic nucleus facilitated social
recognition, and this facilitation was blocked by an oxytocin receptor antagonist injected into, but not outside of, the
medial amygdala. In the medial amygdala, dendrite-like thick oxytocin processes were found to extend from the
supraoptic nucleus. Furthermore, oxytocin treatment restored deﬁcits of social recognition in secretin receptor–
deﬁcient mice.
CONCLUSIONS: The results of our study demonstrate that secretin-induced dendritic oxytocin release from
supraoptic neurons enhances social recognition. The newly deﬁned secretin-oxytocin system may lead to a possible
treatment for social deﬁcits.
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magnocellular and parvocellular neurons of the hypothalamic
paraventricular nucleus (PVN) and in magnocellular neurons of
the supraoptic nucleus (SON) in the hypothalamus, and it is
modestly expressed in the bed nucleus of the stria terminalis
(1,2). Oxytocin in magnocellular neurons is released from the
neurohypophysis into the systemic circulation and has roles in
parturition and lactation (3). Oxytocin is also released from axon
terminals of parvocellular oxytocin neurons and from dendrites
or cell bodies of magnocellular oxytocin neurons (4,5). The
oxytocin receptor is distributed widely within the brain, includ-
ing the olfactory bulb, basal ganglia, hypothalamus, limbic
areas, and brainstem (3,6), suggesting that oxytocin has various
functions in the central nervous system. Growing evidence has
shown that oxytocin modulates social recognition and social
behavior. Animal studies showed that oxytocin increases social
interactions and is involved in partner preference and parental
behavior (7–10). Oxytocin-deﬁcient and oxytocin receptor–& 2016 Society of B
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SEE COMMENTARYdeﬁcient mice show sociobehavioral deﬁcits (11,12). Oxytocin
has also been implicated in disorders associated with dysfunc-
tional social behaviors, including autism spectrum disorders
(10,13–15). For improving social deﬁcits in humans, activation
of endogenous oxytocin neurons, rather than exogenous oxy-
tocin administration, the reported effects of which are con-
troversial, has been proposed to be effective (16).
Secretin, a 27–amino acid peptide hormone that belongs to
the vasoactive intestinal peptide/glucagon/pituitary adenylate
cyclase–active polypeptide family (17), has also been sug-
gested to play a role in the control of social behavior. Secretin
is synthesized in various brain regions, including the hypo-
thalamus, hippocampus, cerebellum, cerebral cortex, and
brainstem (18–21). The secretin receptor is also distributed
widely in the brain, including the brainstem, cerebellum,
cerebral cortex, hypothalamus, and hippocampus (21–24).
Secretin receptor–deﬁcient mice have been suggested to have
deﬁcits in social behavior (25).iological Psychiatry. This is an open access article under the
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 243
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PsychiatryCentral administration of secretin increases oxytocin messenger
RNA expression in the hypothalamus (21). However, the relation-
ship between secretin and oxytocin in the regulation of social
behavior is unknown. In this study, we demonstrated that secretin
activated oxytocin neurons selectively in the SON and potentiated
dendritic oxytocin release. We further investigated whether den-
dritically released oxytocin from the SON facilitated social recog-
nition via the oxytocin receptor in the medial amygdala, where
oxytocin has been shown to facilitate social recognition (26,27).METHODS AND MATERIALS
Animals
Male Wistar rats and male and female C57BL/6J mice were
obtained from Japan SLC, Inc. (Shizuoka, Japan), CLEA Japan,
Inc. (Tokyo, Japan), or Charles River Laboratories Japan
(Kanagawa, Japan). Oxytocin receptor–deﬁcient male mice
(12) and secretin receptor–deﬁcient male mice (25) after back-
crossing with C57BL/6J mice for .11 generations were used.
Adult male animals were used in the present study except
where speciﬁed otherwise. Juvenile male rats and ovariectom-
ized female C57BL/6J mice were used as stimulus animals for
the social recognition test, and 4-week-old male rats were used
for experiments with isolated SON. The animals were housed in
a room with controlled temperature (22 6 21C) and humidity
(40%–70%) with a 12-hour light/dark cycle (lights on 7:30 AM–
7:30 PM). Food and water were available ad libitum. All animals
except the ones used in the experiment, for which results are
shown in Figure 1B and C, were kept in individual cages. All
animal procedures were approved by the Institutional Animal
Experiment Committee of Jichi Medical University and were in
accordance with the Institutional Regulations for Animal Experi-
ments and Fundamental Guidelines for Proper Conduct of
Animal Experiments and Related Activities in Academic
Research Institutions under the jurisdiction of the Ministry of
Education, Culture, Sports, Science and Technology.
Social Recognition Test
A juvenile male rat (21–35 days old) or an ovariectomized female
mouse (.10 weeks old) was presented to an adult male rat or
mouse, respectively, for 4 minutes (training session). After an
interval (30 minutes or 45 minutes), both the same stimulus animal
(familiar) and another stimulus animal (novel) were presented for 4
minutes (test session). Social recognition was estimated by using
a preference index ([time investigating novel animal]/[time inves-
tigating familiar animal 1 time investigating novel animal] 3 100)
(28). As social recognition lasts,40 minutes in rodents (29), a 45-
minute interval between the training and the test was used to
assess facilitative effects of drugs on social recognition. A 30-
minute posttraining interval was used in tests for which results are
shown in Figures 1B and C and 3H, and a 45-minute posttraining
interval was used in tests for which results are shown in
Figures 1D–F and 3A–C and E. Drugs were injected 10 minutes
before the training session, unless otherwise speciﬁed.
Surgery and Intracerebroventricular Injection
Animals were anesthetized with intraperitoneal injection of
200 mg/kg tribromoethanol (Avertin; Wako Pure Chemical244 Biological Psychiatry February 1, 2017; 81:243–251 www.sobp.orIndustries, Ltd., Osaka, Japan) and placed in a stereotactic
frame. Stainless steel guide cannulae (23 gauge for rats or 25
gauge for mice) were inserted into the right lateral cerebral
ventricle (coordinates for rats, .6 mm caudal to the bregma, 1.6
mm lateral to the midline, and 4.5 mm below the skull;
coordinates for mice, .4 mm caudal to the bregma, 1.0 mm
lateral to the midline, and 2.0 mm below the skull) and secured
to the skull with screws and dental cement. Animals were
allowed to recover in individual cages for 1–2 weeks (rats) or
for 2–3 weeks (mice). Animals were given an intracerebroven-
tricular (i.c.v.) injection (30-gauge needle for rats or 31-gauge
needle for mice) of secretin (.1 μg/5 μL, 1 μg/5 μL, 10 μg/5 μL
[rats (1 mg secretin for behavioral and immunohistochemistry
experiments)] or 1 μg/2 μL [mice]) (Tocris Bioscience, Ellisville,
Missouri [rats], Phoenix Pharmaceuticals, Inc., Burlingame,
California [mouse]), a selective oxytocin receptor antagonist
(1 μg/5 μL [rats]; des Gly-NH2-d(CH2)5 [D-Tyr2, Thr4] OVT;
kindly provided by M. Manning, University of Toledo College of
Medicine, Toledo, Ohio) (30), oxytocin (1 ng/2 μL [mice];
Peptide Institute, Inc., Osaka, Japan), or artiﬁcial cerebrospinal
ﬂuid (vehicle; 138 mmol/L sodium chloride, 5 mmol/L potas-
sium chloride, 1.5 mmol/L calcium chloride, 1 mmol/L mag-
nesium chloride, 11 mmol/L sodium bicarbonate, 1 mmol/L
sodium phosphate [pH 7.2]). The position of the injection
needle tip was veriﬁed with methylene blue injected through
the cannula after experiments.
Detection of Activated Neurons After Secretin
Injection
For detection of neurons activated after secretin injection,
male rats, male secretin receptor–deﬁcient mice, or male
oxytocin receptor–deﬁcient mice were given an i.c.v. injec-
tion of secretin (1 μg/5 μL [rats] or 1 μg/2 μL [mice]) or the
vehicle, anesthetized with intraperitoneal injection of 50 mg/
kg pentobarbital (Nembutal; Dainippon Pharmaceutical Co.,
Ltd., Osaka, Japan) 100 minutes after the injection, and
perfused transcardially with heparinized saline (20 U/mL) and
then with 4% paraformaldehyde in .1 mol/L phosphate
buffer (pH 7.4). The brains were removed, postﬁxed in 4%
paraformaldehyde overnight, and transferred to 30%
sucrose solution in .1 ml/L phosphate buffer until tissues
sank. The brains were frozen on dry ice and stored at
2801C. Coronal brain sections were cut at 30 μm with a
freezing sledge microtome. Every fourth (rats) or third (mice)
section of the hypothalamus and medial amygdala was
collected and processed for immunohistochemistry for c-
Fos or oxytocin or both (2,31) (see Supplemental Methods
and Materials for details).
X-gal Staining and Immunohistochemistry for
Oxytocin
For detection of β-galactosidase activity in oxytocin neurons
of the SON in secretin receptor–heterozygous mice,
the mice were perfused transcardially with heparinized saline
(20 U/mL) and then with 4% paraformaldehyde in .1 mol/L
phosphate buffer. Brain sections were cut at 5 μm and
processed for X-gal staining and immunohistochemical detec-
tion of oxytocin (see Supplemental Methods and Materials
for details).g/journal
Figure 1. Secretin facilitates acquisition of social recognition. (A) An adult male rat or mouse (A) was exposed to one stimulus conspeciﬁc animal (S1) in a
training session. After an interval of 30 minutes or 45 minutes, both the S1 stimulus animal and a novel stimulus animal (S2) were presented in a test session.
Because social recognition lasts for ,40 minutes in rodents (29), a 45-minute interval was used to assess facilitative effects of drugs on social recognition. The
preference index was calculated as described in Methods and Materials. (B–F) Social recognition tests in wild-type mice (Sctr1/1; n5 16) and secretin receptor–
deﬁcient mice (Sctr2/2; n 5 18) (B); wild-type mice (Oxtr1/1; n 5 13) and oxytocin receptor–deﬁcient mice (Oxtr2/2; n 5 16) (C); mice after i.c.v. injection of a
vehicle or secretin (n 5 12 for each group) (D); rats after i.c.v. injection of the vehicle (n 5 10) or secretin (n 5 12) (E); and rats after vehicle or secretin injected
i.c.v. before or after the training session (n 5 16 for each group) (F). Test sessions were performed after a 30-minute (B, C) or a 45-minute (D–F) interval.
Secretin receptor–deﬁcient mice and oxytocin receptor–deﬁcient mice showed a deﬁcit in social recognition. The i.c.v. administration of secretin before, but not
after, training facilitated social recognition. Error bars indicate SEM. ***p , .001 vs. vehicle-injected animals (Mann-Whitney U test; (D) U 5 9, p 5 .0003;
(E) U 5 112, p 5 .0006); *p , .05, **p , .01 vs. rats injected with secretin before training (one-way analysis of variance followed by Bonferroni-Dunn posttest;
(F) [F2,455 6.959, p5 .0023]).
1p, .05 vs. wild-type mice (Mann-Whitney U test; (B) U 5 79, p 5 .0249; (C) U5 54, p 5 .0283). ns, #p , .05, ##p , .01, periods
of time investigating familiar vs. novel animals (Wilcoxon signed rank test; (B) Sctr1/1, t 5 27, p 5 .034, Sctr2/2, t 5 76, p 5 .6791; (C) Oxtr1/1, t 5 15,
p 5 .0330, Oxtr2/2, t 5 60, p 5 .6791; (D) VEH, t 5 33, p 5 .6379, SCT, t 5 0, p 5 .0022; (E) VEH, t 5 11, p 5 .0926, SCT, t 5 3, p 5 .0047; (F) Before [SCT],
t 5 15, p 5 .0061, After [VEH], T 5 39, p 5 .1337, After [SCT], t 5 64, p 5 .8361). i.c.v., intracerebroventricular; ns, not signiﬁcant; SCT, secretin; VEH, vehicle.
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Injection
Trunk blood of rats was collected by decapitation at 5, 15, 30,
and 60 minutes after i.c.v. injection of secretin (1 μg/5 μL) or
the vehicle for time-course analysis and at 15 minutes after
i.c.v. injection of secretin (.1, 1, 10 μg/5 μL) or the vehicle for
dose-dependency analysis. Plasma samples were obtained by
centrifugation. Plasma concentrations of oxytocin were deter-
mined by a radioimmunoassay with speciﬁc anti-oxytocin (32)
as described previously (33). Coefﬁcients of intra-assay andBiological Psyinterassay variations were 4% and 10% for oxytocin, respec-
tively. The minimum detection limit was 2 pg/mL for oxytocin.
Measurement of Oxytocin Release From Isolated SON
Brains were obtained from male rats (Slc:Wistar; Japan SLC) at
4 weeks of age by decapitation. Two blocks of basal hypo-
thalamic tissues (2 mm 3 1 mm 3 1 mm) containing the SON
were dissected out from each brain under a dissecting micro-
scope (31). The blocks were transferred to normal Locke’s buffer
solution (140 mmol/L sodium chloride, 5 mmol/L potassiumchiatry February 1, 2017; 81:243–251 www.sobp.org/journal 245
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Psychiatrychloride, 1.2 mmol/L magnesium chloride, 2.2 mmol/L calcium
chloride, 10 mmol/L glucose, 10 mmol/L N-2-hydroxyethylpi-
perazine-N-2-ethanesulfonic acid [pH 7.2]) and maintained at
371C throughout the experiments. The normal Locke’s buffer
solution was changed at 5-minute intervals for 60 minutes
before collecting the samples. After the preincubation period,
samples were collected every 5 minutes in a volume of 200 μL
until the end of the experiment. Secretin at a concentration of 2
μmol/L or 10 μmol/L was applied for 15 minutes. The collected
samples were immediately stored at 2801C until radioimmuno-
assay for oxytocin. Stimulus-evoked hormone release during
drug application at each dosage is presented as the amount of
hormone released compared with basal release (fraction before
application of secretin or the vehicle).
Surgery and Microinjection
Rats were anesthetized with Avertin and placed in a stereotactic
frame. Stainless steel guide cannulae (23 gauge) were inserted into
the brain so that tips of the injection cannulae were located in the
right SON (coordinates for the tips of guide cannulae, 1.8 mm
caudal to the bregma, 1.8 mm lateral to the midline, and 7.1 mm
below the skull) or the right medial amygdala (coordinates,
2.3 mm caudal to the bregma, 3.2 mm lateral to the midline,
and 7.4 mm below the skull) and secured to the skull with screws
and dental cement. The tip of the injection needle (30 gauge)
extended 1.8 mm beyond the guide cannulae. The position of the
tip was veriﬁed with methylene blue injected through the cannula
after experiments (Supplemental Figure S1). Animals were allowed
to recover from the surgical operation of cannula implantation for 2
weeks. Rats were injected with secretin (.1 μg/.5 μL) or the vehicle
into the SON and with an oxytocin receptor antagonist (.1 μg/.5 μL)
or artiﬁcial cerebrospinal ﬂuid vehicle into the medial amygdala.
Detection of Dendrite-like Processes of Oxytocin
Neurons From SON
Male rats were perfused and brains were isolated as described
earlier. Coronal brain sections were cut at 50 μm and
processed for immunohistochemical detection of oxytocin by
use of a light microscope (Supplemental Methods and
Materials).
For electron microscopic examination, male rats were perfused
with a solution containing 4% paraformaldehyde, .1% glutaralde-
hyde, and .3% tannic acid in .1 mol/L phosphate buffer. Brain
sections were cut and processed for electron microscopic analysis
(34) (Supplemental Methods and Materials).
Data Analysis
Data were analyzed by the Mann-Whitney U test, Student t
test, two-way analysis of variance, or one-way analysis of
variance followed by Bonferroni-Dunn or Dunnett’s multiple
comparison tests. Social recognition data were also analyzed
by the Wilcoxon signed rank test (investigation time for familiar
mice vs. investigation time for novel mice). A value of p , .05
was considered to be statistically signiﬁcant.
RESULTS
Mice or rats were exposed to one stimulus conspeciﬁc animal
in a training session; after an interval, both the previously246 Biological Psychiatry February 1, 2017; 81:243–251 www.sobp.orexposed familiar stimulus animal and a different novel stimulus
animal were introduced to the animal (Figure 1A). Wild-type
mice spent more time investigating a novel mouse than
investigating a previously exposed familiar mouse and thus
showed a preference index of .50 (Figure 1B, C), suggesting
that wild-type mice discriminated between novel and familiar
mice. On the other hand, secretin receptor–deﬁcient mice
(Figure 1B) and oxytocin receptor–deﬁcient mice (Figure 1C)
investigated a novel mouse and familiar mouse equally and
thus showed a smaller preference index than wild-type mice,
suggesting that not only the oxytocin receptor but also secretin
receptor plays a facilitative role in social recognition. This kind
of short-term social recognition lasts for ,40 minutes in
rodents (29). Vehicle-injected mice and rats spent similar
periods of time investigating the familiar stimulus and novel
stimulus animals and thus showed a preference index of 50
when tested 45 minutes after training (Figure 1D, E), suggesting
that rodents no longer discriminated between familiar and
novel stimulus animals. However, following secretin adminis-
tration before the training session, mice and rats spent a longer
time investigating the novel stimulus animals at testing than
investigating the familiar stimulus animals and thus showed an
increased preference index compared with that of vehicle-
injected animals, suggesting that secretin facilitated social
recognition (Figure 1D, E). We then examined whether secretin
facilitates acquisition, consolidation, or recall of social recog-
nition. Secretin administration before, but not after, the training
facilitated social recognition (Figure 1F). These ﬁndings sug-
gest that secretin acts in the acquisition phase to facilitate
social recognition rather than acting in consolidation or recall.
To clarify whether secretin activates oxytocin neurons, we
examined the expression of c-Fos, a marker of neuronal
activation, in oxytocin neurons after i.c.v. injection of secretin.
The number of c-Fos–positive oxytocin neurons was signiﬁ-
cantly increased after i.c.v. injection of secretin in the SON but
not in the PVN and bed nucleus of the stria terminalis
(Figure 2A, B), suggesting that i.c.v. secretin preferentially
activates oxytocin neurons in the SON. To determine whether
secretin activates oxytocin neurons via activation of the
secretin receptor, we examined the expression of c-Fos in
oxytocin neurons of secretin receptor–deﬁcient mice. An
increase in the number of c-Fos–positive oxytocin neurons in
the SON after secretin injection was blocked in secretin
receptor–deﬁcient mice (Figure 2C), suggesting that secretin
activates oxytocin neurons via the secretin receptor. We then
examined whether oxytocin neurons in the SON express the
secretin receptor. In order to identify cells expressing the
secretin receptor, we examined the expression of β-galacto-
sidase, for which the gene was inserted in a secretin receptor–
knockout vector as a reporter gene. In secretin receptor–
heterozygous mice, but not in wild-type mice, β-galactosidase
activity was evident in oxytocin neurons in the SON suggest-
ing that oxytocin neurons in the SON express the secretin
receptor (Figure 2D and Supplemental Figure S2).
We then examined whether secretin facilitates oxytocin
release. After i.c.v. injection of secretin, the plasma concen-
tration of oxytocin increased and peaked at 5 minutes
(Figure 2E), and the increase was dose dependent
(Figure 2F). Blood hemoglobin concentration, plasma osmo-
lality, and plasma glucose concentration were not signiﬁcantlyg/journal
Figure 2. Secretin activates supr-
aoptic oxytocin neurons and facili-
tates dendritic oxytocin release.
(A) Percentages of oxytocin-immu-
noreactive cells expressing c-Fos, a
marker for neuronal activity, after i.c.v.
injection of secretin or the vehicle
in rats (n 5 8 for each group).
(B) Photographs showing c-Fos
immunoreactivity (black nuclei) in oxy-
tocin neurons (brown cytoplasm) of
the supraoptic nucleus (SON) after i.c.
v. injection of secretin or the vehicle.
The i.c.v. administration of secretin
activated oxytocin neurons preferen-
tially in the SON. (C) Percentage of
supraoptic oxytocin neurons expres-
sing c-Fos after i.c.v. injection of
secretin or the vehicle in wild-type
and secretin receptor–deﬁcient mice
(n 5 4–6 for each group). (D) Photo-
graphs showing X-gal staining and
immunohistochemistry for oxytocin in
wild-type and secretin receptor–het-
erozygous (Sctr1/2) mice (n 5 5 for
each group). Supraoptic oxytocin
neurons have the secretin receptor.
(E, F) Time-course (E) and dose-
dependency (F) analyses of plasma
oxytocin concentrations after i.c.v.
injection of secretin or the vehicle in
rats (n 5 6–8 for each group).
(G) Oxytocin release from isolated
SON preparations after secretin appli-
cation (n 5 8–10 for each group).
(H) Increase in oxytocin released from
isolated SON by exposure to each
concentration of secretin. Secretin
administration facilitated oxytocin
release from axon terminals in the
neurohypophysis and from dendrites
in the SON. Error bars indicate SEM.
*p , .05, **p , .01, ***p , .001 vs.
vehicle-injected animals (Student t
test; (A) bed nucleus of the stria
terminalis, [t14 5 2.5911, p 5 .5639],
hypothalamic paraventricular nucleus,
[t14 5 2.3388, p 5 .7398], SON, [t14 5
24.700, p 5 .0003]; one-way analysis
of variance [ANOVA] followed by Bon-
ferroni-Dunn posttest; (C) [F3,17 5
5.5327, p 5 .0078]; two-way ANOVA
and Bonferroni-Dunn posttest;
(E) [F1,44 5 63.2123, p 5 4.7500 3
10210, effects of drug], [F3,44 5
8.5816, p 5 .0001, effects of time],
[F3,44 5 6.1171, p 5 .0014, interac-
tion]; one-way ANOVA followed by Dunnett’s posttest; (F) [F3,22 5 8.6922, p 5 .0005]; (H) [F2,23 5 23.8741, p 5 2.4442 3 10
26]). 1p , .05, 11p , .01 vs.
corresponding control animals (one-way (C) or two-way (E) ANOVA followed by Bonferroni-Dunn posttest). Scale bars 5 20 μm. BNST, bed nucleus of the
stria terminalis; i.c.v., intracerebroventricular; oxytocin-ir, oxytocin-immunoreactive; PVN, paraventricular nucleus; SCT, secretin; VEH, vehicle.
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Psychiatrychanged after secretin injection (Supplemental Figures S3 and
S4), suggesting that the increase in oxytocin release observed
after secretin injection was not caused by changes in blood
volume, blood osmolality, or blood glucose concentration. In
order to determine whether secretin also facilitates oxytocin
release from soma or dendrites, we examined oxytocin release
from isolated SON explants. After application of secretin toBiological Psyisolated SON explants, oxytocin concentrations in the perfu-
sates were signiﬁcantly increased in a dose-related fashion
(Figure 2G, H). These results suggest that secretin activates
oxytocin neurons and facilitates not only peripheral oxytocin
release but also somatodendritic oxytocin release.
To determine whether secretin facilitates social recognition
via oxytocin, we examined the effects of an oxytocin receptorchiatry February 1, 2017; 81:243–251 www.sobp.org/journal 247
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was blocked by i.c.v. coadministration of an oxytocin receptor
antagonist (Figure 3A), suggesting that activation of the oxy-
tocin receptor is essential for facilitation of social recognition
by secretin. Furthermore, a secretin-induced increase of the
preference index was not observed in oxytocin receptor–
deﬁcient mice (Figure 3B). Because i.c.v. injection of secretin
activated oxytocin neurons in the SON (Figure 2A, B) and
supraoptic oxytocin neurons expressed the secretin receptor
(Figure 2D), we examined whether activation of oxytocin
neurons in the SON by microinjection of secretin facilitates
social recognition. After microinjection of secretin into the
SON, rats showed preferential investigation toward novel
juvenile stimulus rats and thus showed an increased prefer-
ence index compared with vehicle-injected rats (Figure 3C).
However, rats injected with secretin outside of the SON spent
similar periods of time investigating the familiar stimulus and
novel stimulus rats (Wilcoxon signed rank test, t 5 32, p 5
.9292) and thus showed a preference index of 50 (49.7 6
2.9, mean 6 SEM, n 5 11). These results suggest that secretin
acted within or in the vicinity of the SON to facilitate social
recognition.
The oxytocin receptor is expressed in the medial amygdala
(6), and oxytocin has been shown to act on the medial
amygdala to facilitate social recognition (26). It is possible
that secretin activates oxytocin neurons in the SON, stimu-
lates the oxytocin receptor in the medial amygdala, and as a
result facilitates social recognition. Consistent with this view,
we found that i.c.v. administration of secretin resulted in an
increase in the number of c-Fos–positive cells in the medial
amygdala of mice (Figure 3D) and rats (Supplemental Figure
S5) and that secretin-induced c-Fos expression was blocked
by deﬁciency of the oxytocin receptor in mice (Figure 3D). We
further examined the effects of microinjection of an oxytocin
receptor antagonist into the medial amygdala. Facilitation of
social recognition induced by injection of secretin into the
SON was blocked after microinjection of an oxytocin receptor
antagonist into the medial amygdala but not after micro-
injection of the antagonist outside the medial amygdala
(Figure 3E).
All the results suggest that activation of supraoptic oxytocin
neurons induces stimulation of the oxytocin receptor in the
medial amygdala. The medial amygdala contains oxytocin
ﬁbers, but it has been reported that oxytocin neurons in the
SON do not project to the medial amygdala (35). Thus, we
examined whether the medial amygdala contains dendrites of
oxytocin neurons, as oxytocin was released from dendrites of
oxytocin neurons after application of secretin (Figure 2G, H).
Oxytocin-immunoreactive ventrally projected thick spinous
processes, which are characteristics of oxytocin dendrites,
were found to extend from the SON into the anteroventral part
of the medial amygdala (Figure 3F). Electron microscopic
examination revealed that the medial amygdala contained
dendrites and axons of oxytocin neurons (Figure 3G). These
ﬁndings are consistent with the idea that oxytocin is released
directly in the medial amygdala from dendrites of supraoptic
oxytocin neurons.
We also examined the action of oxytocin in secretin
receptor–deﬁcient mice. After oxytocin administration, secretin
receptor–deﬁcient mice showed preferential investigation248 Biological Psychiatry February 1, 2017; 81:243–251 www.sobp.ortoward novel stimulus animals and showed a preference index
that was as high as wild-type animals (Figure 3H), suggesting
that oxytocin restored deﬁcits in social recognition of secretin
receptor–deﬁcient mice and that facilitative action of oxytocin
on social recognition is not dependent on the secretin
receptor.DISCUSSION
In the present study, we found that secretin facilitates oxytocin
release from the SON and facilitates social recognition.
Facilitative effects of secretin on social recognition were
blocked by a selective oxytocin receptor antagonist injected
into the medial amygdala and by deﬁciency of the oxytocin
receptor. These ﬁndings suggest that secretin facilitates social
recognition via activation of the oxytocin receptor within or in
the vicinity of the medial amygdala.
Social recognition memory is composed of at least three
phases: acquisition, consolidation, and recall. Oxytocin has
been shown to facilitate acquisition of social recognition (26). It
has been suggested that secretin receptor–deﬁcient mice
have deﬁcits in social recognition (25). In the present study,
secretin injected before, but not after, the acquisition phase
facilitated social recognition memory. These results demon-
strated that secretin as well as oxytocin facilitates acquisition,
but not consolidation or recall, of social recognition. The
results are consistent with the view that secretin facilitates
social recognition via the oxytocin–oxytocin receptor system.
Application of secretin to the SON facilitated oxytocin
release and enhanced social recognition via the oxytocin
receptor within or in the vicinity of the medial amygdala. It
remains to be clariﬁed how stimulation of supraoptic oxytocin
neurons induced activation of the oxytocin receptor in the
medial amygdala. Stimulation of supraoptic oxytocin neurons
might have induced somatodendritic oxytocin release within
the SON, from where released oxytocin may reach the medial
amygdala by diffusion. Because the medial amygdala contains
oxytocin ﬁbers (36), it is also possible that oxytocin was
released from oxytocin ﬁbers within the medial amygdala.
Electron and light microscopic examinations in the present
study demonstrated that both dendrites and axons of oxytocin
neurons existed within the medial amygdala and suggested
that oxytocin-positive, dendrite-like processes extended from
the SON into the anteroventral part of the medial amygdala.
Oxytocin-containing axon ﬁbers were reported to originate
from oxytocin neurons in the PVN, but not from oxytocin
neurons in the SON (35). These ﬁndings are consistent with
the view that activation of supraoptic oxytocin neurons
induced oxytocin release from dendrites within the SON or
dendrites extending from the SON into the medial amygdala
and as a result facilitates social recognition. This view does
not exclude roles of PVN oxytocin neurons projecting to the
medial amygdala in social recognition. Possible functional
differences between SON and PVN oxytocin neurons in the
control of social recognition remain to be clariﬁed.
The present study suggests involvement of the oxytocin–
oxytocin receptor system in secretin-induced facilitation of
social recognition. However, secretin has been reported to
activate hypothalamic vasopressin neurons (21), and vaso-
pressin has afﬁnity to the oxytocin receptor (37). Thus,g/journal
Figure 3. Activation of supraoptic
oxytocin neurons by secretin facili-
tates social recognition via the oxyto-
cin receptor in the medial amygdala.
(A–C) Social recognition tests in rats
after i.c.v. injection of secretin or the
vehicle with coadministration of an
oxytocin receptor antagonist (n 5 14)
or the vehicle (n 5 15) (A), oxytocin
receptor–deﬁcient mice after i.c.v.
injection of secretin (n 5 13) or the
vehicle (n 5 17) (B), and rats with
microinjection into the supraoptic
nucleus (SON) of secretin or the vehi-
cle (n 5 9 for each group) (C). The
i.c.v. injection of secretin or microin-
jection of secretin into the SON
facilitated social recognition, and
secretin-induced facilitation of social
recognition was impaired by an oxyto-
cin receptor antagonist or in oxytocin
receptor–deﬁcient mice. (D) Number
of c-Fos-immunoreactive cells in the
medial amygdala after i.c.v. injection
of secretin in wild-type and oxytocin
receptor–deﬁcient mice (n 5 6 for
each group). The i.c.v. administration
of secretin activated the medial amyg-
dala. (E) Social recognition tests in
rats with microinjection of secretin into
the SON and into the medial amygdala
with an oxytocin receptor antagonist
or the vehicle (n 5 12 for each group;
left panel) and in rats with microinjec-
tion of secretin into the SON (On
target) and into (On target) and outside
of the medial amygdala (Off target)
with an oxytocin receptor antagonist
(n 5 10 for each group; right panel).
Secretin injected into the SON facili-
tated social recognition, and secretin-
induced facilitation was blocked by an
oxytocin receptor antagonist injected
into the medial amygdala. (F) Photo-
graphs showing dendrite-like pro-
cesses extending into the medial
amygdala from oxytocin-immunoreac-
tive cells in the SON of rats. Insets are
enlargements of the areas enclosed by
rectangles. Scale bars 5 40 μm. (G)
Electron microscopic photographs of
oxytocin-immunoreactive dendrite (left
panel) and oxytocin-immunoreactive
axon (right panel) in the medial amyg-
dala. Scale bar 5 1 μm. (H) Social
recognition tests in wild-type mice (n 5 12) and secretin receptor–deﬁcient mice (n 5 16) after i.c.v. injection of oxytocin. After oxytocin administration, secretin
receptor–deﬁcient mice showed social recognition at a level as high as that in wild-type mice. Test sessions were performed after a 45-minute (A–C, E) or a 30-
minute (H) interval. Error bars indicate SEM. ns, *p , .05, **p , .01, ***p , .001 vs. vehicle-injected animals, and ns, 11p , .01 vs.wild-type mice (one-way
analysis of variance followed by Bonferroni-Dunn post-test; (A) [F3,55 5 9.3930, p 5 4.1375 3 10
25]; (D) [F3,20 5 10.1771, p 5 .0003]; Mann-Whitney U test; (B)
U 5 122, p 5 .6303; (C) U 5 67, p 5 .0193; (E) SCT 1 VEH vs. SCT 1 OXTR antagonist, U 5 14, p 5 .0008, SCT 1 OXTR antagonist (On target) vs. SCT 1
OXTR antagonist (Off target), U 5 90.5, p 5 .0022; (H) U 5 101, p 5 .8165). ns, #p , .05, ##p , .01, periods of time investigating familiar vs. novel animals
(Wilcoxon signed rank test; (A) VEH 1 VEH, t 5 42, p 5 .3066, SCT 1 VEH, t 5 4, p 5 .0015, VEH 1 OXTR antagonist, t 5 52, p 5 .6496, SCT 1 OXTR
antagonist, t 5 34, p 5 .2455; (B) VEH, t 5 70, p5 .7583, SCT, t 5 42, p5 .8068; (C) VEH, t 5 14, p5 .3139; SCT, t 5 2, p 5 .0152; (E) SCT1 VEH, t 5 2, p 5
.0037, SCT 1 OXTR antagonist, t 5 33, p 5 .6379, SCT 1 OXTR antagonist (On target), t 5 11, p 5 .1731, SCT 1 OXTR antagonist (Off target), t 5 2, p 5
.0093; (H) Sctr1/1, t 5 13, p 5 .0414, Sctr2/2, t 5 18, p 5 .0097). i.c.v., intracerebroventricular; MeA, medial amygdala; ns, not signiﬁcant; OXT, oxytocin; OXT-
ir, oxytocin-immunoreactive; OXTR, oxytocin receptor; SCT, secretin; VEH, vehicle.
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following secretin, although vasopressin has been shown to
facilitate consolidation or recall of social recognition (38),
which apparently contradicts the observed facilitative action
of secretin on acquisition of social recognition. Roles of
vasopressin in the control of social recognition following
secretin need to be evaluated by further studies.
Neurosecretory neurons in the SON contain secretory
vesicles in their cell bodies and dendrites, and they release
peptides packed in the vesicles somatodendritically within the
SON (5). Secretin has been shown to be synthesized and
released from magnocellular neurosecretory neurons (21). The
magnocellular oxytocin neurons in the hypothalamus have
been suggested to be activated by social stimuli, including
afﬁliative gaze and touches (7–16,39,40). Considering the
results suggesting that the secretin receptor is expressed in
oxytocin neurons, it is tempting to speculate that social stimuli
activate supraoptic neurosecretory neurons and induce den-
dritic secretin release within the SON from neurosecretory
neurons, leading to activation of the secretin receptor of their
own or neighboring neurosecretory neurons to modulate
activity of oxytocin neurons and as a result facilitate social
recognition.
In the present study, secretin was administered centrally at
doses of .1–10 μg. The doses appear to be relatively high,
considering the reported in vitro afﬁnity of the secretin
receptor binding, as reported values of dissociation constant
or inhibition constant were between .2 nmol/L and 20 nmol/L
(22,41–43). However, secretin concentrations at action sites of
secretin were not determined in the present study. Previous
in vivo studies using animals showed that similar doses of
secretin that were centrally administered affected behaviors
such as food intake, water intake, and locomotion (44–47).
Furthermore, in the present study, effects of secretin were
blocked by deﬁciency of the secretin receptor, and oxytocin
neurons were shown to express the secretin receptor. All
these ﬁndings suggest that the action of secretin observed in
the present study was mediated by the secretin receptor
expressed in oxytocin neurons. However, peripheral admin-
istration of secretin at a dose of .1–1 μg in rats was reported to
activate supraoptic oxytocin neurons and facilitate oxytocin
release (48). This action by peripheral secretin is mediated by
central noradrenergic projections to the SON (48) and thus is
likely to be distinct from a direct action of secretin on oxytocin
neurons suggested by the results of the present study.
In conclusion, our ﬁndings provide evidence that oxytocin
released somatodendritically from supraoptic oxytocin neu-
rons by local secretin acts on the oxytocin receptor within or in
the vicinity of the medial amygdala during the acquisition
phase and, as a result, facilitates social recognition. Enhance-
ment of endogenous oxytocin release has been proposed to
be most effective for improving social recognition (16). Phar-
macologically inducing dendritic oxytocin release may lead to
therapy for psychiatric disorders with social deﬁcits.ACKNOWLEDGMENTS AND DISCLOSURES
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